Daniel R. Chevallard
Net Worth
Last updated:
What is Daniel R. Chevallard net worth?
The estimated net worth of Mr. Daniel R. Chevallard is at least $1,773,358 as of 27 Feb 2024. He owns shares worth $1,001 as insider, has earned $99,357 from insider trading and has received compensation worth at least $1,673,000 in Viracta Therapeutics, Inc..
What is the salary of Daniel R. Chevallard?
Mr. Daniel R. Chevallard salary is $418,250 per year as Chief Financial Officer, Chief Operating Officer & Sec. in Viracta Therapeutics, Inc..
How old is Daniel R. Chevallard?
Mr. Daniel R. Chevallard is 45 years old, born in 1980.
What stocks does Daniel R. Chevallard currently own?
As insider, Mr. Daniel R. Chevallard owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Viracta Therapeutics, Inc. (VIRX) | Chief Financial Officer, Chief Operating Officer & Sec. | 102,306 | $0.01 | $1,001 |
What does Viracta Therapeutics, Inc. do?
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Daniel R. Chevallard insider trading
Viracta Therapeutics, Inc.
Mr. Daniel R. Chevallard has made 11 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,405 units of VIRX stock worth $2,492 on 27 Feb 2024.
The largest trade he's ever made was exercising 13,777 units of VIRX stock on 25 Nov 2021. As of 27 Feb 2024 he still owns at least 102,306 units of VIRX stock.
Viracta Therapeutics key executives
Viracta Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Ivor Royston M.D. (79) Chief Executive Officer, Pres & Director
- Dr. Lisa Rojkjaer (59) Chief Medical Officer
- Mr. Daniel R. Chevallard (45) Chief Financial Officer, Chief Operating Officer & Sec.